文献速递妇科

多重分析识别卵巢癌腹腔内化疗期间独特的局部和全身变化:一项NRG肿瘤学/妇科肿瘤学组研究

Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
PubMed 文献 · Gynecol Oncol · 2017-05-05

该试点研究从13名接受腹腔内化疗的卵巢癌患者中采集全血、腹腔积液和腹腔冲洗液样本,评估多重生物标志物分析的可行性。结果显示腹腔积液具有不同于血液的独特生物标志物谱,miRNA比基因更早发生化疗相关改变,流式细胞术不能充分捕捉生物标志物波动。

要点

  • 从13名患者采集30份全血、12份腹腔积液和20份腹腔冲洗液样本。
  • 腹腔积液具有不同于血液的独特生物标志物谱。
  • miRNA比基因更早发生化疗相关改变。

核心结论

  • 作为原理验证研究,该试验提供证据表明腹腔采样可适用于生物标志物分析。

研究设计与样本

  • 试点研究,纳入13名参与GOG 252的女性,采集30份全血、12份腹腔积液和20份腹腔冲洗液(30mL生理盐水)。
  • 样本在最初三个化疗周期前采集,评估体积、细胞群体、蛋白质、RNA和miRNA含量变化。

主要发现

  • 腹腔积液体积中位数为1.6mL,腹腔冲洗液为3.1mL。
  • 腹腔冲洗液是腹腔积液的稀释液,能够捕获可测量的生物标志物。
  • 腹腔积液含有不同于血液的独特生物标志物谱。
  • miRNA比基因更早发生化疗相关改变。
  • 流式细胞术不能充分捕捉生物标志物波动。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Ovarian cancer leads to abdominal carcinomatosis and late stage (III/IV) diagnosis in 75% of patients. Three randomized phase III trials have demonstrated that intraperitoneal (IP) chemotherapy improves outcomes in epithelial ovarian cancer. While IP treatment is validated by clinical trials, there is a poor understanding of the mechanism(s) leading to the survival advantage other than the increased concentration of cytotoxic drugs within the tumor microenvironment. A better understanding of this process through analysis of dynamic biomarkers should promote novel approaches that may enhance tumor clearance. We propose this pilot study to confirm the feasibility of collecting serial peritoneal samples from implanted catheters in women receiving IP chemotherapy. We believe these specimens may be used for multiplex analysis to reveal unique biomarker fluctuations when compared to peripheral blood. METHODS: From 13 women participating on GOG 252, 30 whole blood, 12 peritoneal fluid (PF), and 20 peritoneal wash (PW) with 30mL saline were obtained. Samples were requested prior to the first three chemotherapy cycles. Samples were assessed for volume, cell populations, protein, RNA, and miRNA content changes. RESULTS: Median volume for PF was 1.6mL and 3.1mL for PW. PW is a dilution of PF capable of capturing measurable biomarkers. Peritoneal aspirates contain a unique profile of biomarkers distinct from blood. miRNA undergo earlier alteration with chemotherapy than genes. Flow cytometry does not adequately capture biomarker fluctuations. CONCLUSIONS: As a proof of principle study, this trial provides evidence that sampling the peritoneal cavity can be adapted for biomarker analysis.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Grabosch S, Tseng G, Edwards RP, et al. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2017. PMID: 28483269. doi:10.1016/j.ygyno.2017.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。